Well certainly if there are tox issues we aren't aware of (the 900mg BID are known to some degree) but ITMN hasn't (under Dan Welch) mislead investors to that degree. You do realize that 7227 will not go forward at the 300 TID or 600 BID dose in SOC studies and the INFORM studies regardless of what the 2B results show late Q1/early Q2? Its going forward with lower dosing (probably 100mg BID or 200mg QD if I were to guess) in combo with ritonavir to boost it.
Market Data 
Markets 
AI
